Fenistil New

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

dimetindene (dimetindene maleate)

Доступна с:

Novartis Consumer Health S.A.

ИНН (Международная Имя):

dimetindene (dimetindene maleate)

дозировка:

1mg/ml

Фармацевтическая форма:

drops oral (solution)

Тип рецепта:

OTC

Характеристики продукта

1
Regulatory Affairs
FENISTIL® 1 MG/ML ORAL DROPS
Dimethindene maleate
SUMMARY OF PRODUCT CHARACTERISTICS
Author:
Manuela Bezzi
Document type:
SPC
Document status:
Final
Release date:
13 September, 2005
Number of pages:
7
Property of Novartis Consumer Health SA
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis Consumer Health SA
2
TABLE OF CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
.................................................................... 3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
................................. 3
3.
PHARMACEUTICAL FORM.
..........................................................................
3
4.
CLINICAL PARTICULARS
...............................................................................
3
4.1 Therapeutic indications.
.......................................................................................
3
4.2.
Posology and method of administration
................................................................ 3
4.3.
Contra-indications
................................................................................................
4
4.4.
Special warnings and special precautions for use
.................................................. 4
4.5.
Interactions with other medicinal products and other forms of
interaction. ........... 4
4.6.
Pregnancy and lactation.
......................................................................................
4
4.7.
Effects on ability to drive and use machines.
........................................................ 5
4.8.
Undesirable effects.
.............................................................................................
5
4.9.
Overdose
..............................................................................................................
5
5.
PHARMACOLOGICAL PROPERTIES.
............................................................ 5
5.1.
Pharmacodynamic properties
................................................................................
5
5.2.
Pharm